(Date:11/21/2008)...swire-USNewswire/ -- The Generic,Pharmaceutical A... today from,GPhA President and CEO Kathleen Jaege...undtable on "Emerging Health Care Competition and ... FTC is conducting this roundtable demonstrates th... have access to safe and,affordable biogenerics s...
(Date:11/21/2008)...Newswire-USNewswire/ -- New research at West Virg... spitless tobacco product aimed at young adults is...RJ Reynolds, Camel Snus - touted as a socially acc...singly high levels of nicotine. , , "Camel ...products," said Bruce Adkins of the state Division...
(Date:11/21/2008)... Today, prescription drug... treating 88 percent of patients suffering chronic...for a chronic condition account for 96 percent of ...ll medical costs. A proprietary new pharmacy mode...ions, Inc. (NYSE: MHS ) significantly reduces cr...
(Date:11/21/2008)...- In a statewide survey, 33 physicians credentiale...t Presbyterian Hospital of Dallas were honored by ...per Doctors ." , , Each year, the publisher...dia, Inc. to survey more than 38,000 medical profe... needed medical care, which doctor would you choos...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2... proposes to change the curriculum for medicine by...hopes to implement it within two years. "Today's ...towards integration of both the modern and traditi...It is expected to come out within two years time,"...
...mmon cancer affecting men and occurs in men 65 yea...of 50 years should undergo the routine examination...tate Specific Antigen, by monitoring the levels of... family history of the disease should begin regula...
...ore women are now opting for painless natural chil...e September issue of the journal Anesthesiology, a...ecome more varied and sophisticated, growing numbe...ntage of pain relief for their childbirth. Researc...
...iotics for acne for more than six weeks were more ...ry tract infection within one year as individuals ..., according to latest study reports. Overuse of an...ble for drug resistance and an associated increase...
Other Medicine News:(Date:11/20/2008)... , , , , PHILADELPHIA, Nov. 20 /P...K ) today announced that the United States Food an...proval for PROMACTA(R) (eltrombopag) for the treat...immune (idiopathic) thrombocytopenic purpura (ITP)...teroids, immunoglobulins or splenectomy. The appro...
(Date:11/20/2008)... RIVERSIDE, Calif., Nov. 20 Milk....better than originally thought. After years of,re...vered peptides found in,cow,s milk that stimulate..., To view the Multimedia News Release, go to:... , , While developing new cancer therapi...
(Date:11/20/2008)... CAMBRIDGE, Mass., Nov. 20 Radius...sed an additional $15 million to its second instit... investment to $82.5 million and the total amount ...lion. All existing institutional investors partici...tegic Fund and including MPM Capital, The Wellcome...
(Date:11/20/2008)... TROMSO, Norway, November 20 ...ytix Biopharma has announced results of studies on...ted at ICAAC in Washington, DC,the studies showe...-rapid,bacteriocidal effect, significantly better...ococcus pyogenes than marketed gold standard drugs...
Breaking Medicine Technology:FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Welsh Self Test to Cure Glaucoma the Leading Cause of Preventable Blindness 15540 1New Welsh Self Test to Cure Glaucoma the Leading Cause of Preventable Blindness 15540 2OB Challenges Create Hospital Opportunities in 2008 15535 1OB Challenges Create Hospital Opportunities in 2008 15535 2OB Challenges Create Hospital Opportunities in 2008 15535 3OB Challenges Create Hospital Opportunities in 2008 15535 4New Data Showed ACTOS 28R 29 28pioglitazone HCl 29 Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes 1643 1New Data Showed ACTOS 28R 29 28pioglitazone HCl 29 Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes 1643 2New Data Showed ACTOS 28R 29 28pioglitazone HCl 29 Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes 1643 3New Data Showed ACTOS 28R 29 28pioglitazone HCl 29 Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes 1643 4New Data Showed ACTOS 28R 29 28pioglitazone HCl 29 Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes 1643 5ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 15532 1ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 15532 2... WIRE)--Apr 5, 2007 - MIV Therapeutics Inc.,(OTCBB...ration,biocompatible coatings and advanced drug de... implantable medical devices, today,announced that...hat,merging Biosync Scientific,s certified bare me...with the Company,s polymer-free drug,delivery syst...
... Present Results at 2007 American Association for,...9, 2007 /PRNewswire-FirstCall/ -- Cleveland,BioLab... of,Protectan CBLB502,s efficacy as a mitigator of...e marrow/blood,production) radiation-induced damag...tific Officer, Andrei Gudkov, Ph.D, D. Sci.,will ...
Other Medicine Technology:MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 2Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 3Bras and Breast Support
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication
...lbumin Cobalt Binding (ACB®) Test is a clinica...lbumin (IMA®) by measuring the cobalt binding ...st identified in the early 1990s, IMA is produced ...hemic tissue in the heart. During ischemia, the N-...
...lbumin Cobalt Binding (ACB®) Test is a clinica...lbumin (IMA®) by measuring the cobalt binding ...st identified in the early 1990s, IMA is produced ...hemic tissue in the heart. During ischemia, the N-...
Medicine Products: